6 results about "Propynyl" patented technology

The invention relates to blends from iodopropargyl compound-containing and nitrogen-containing polymers with at least two beta aminoamine functions, to the preparation of these blends and to the use of these blends for the protection of technical materials from destruction by microorganisms, and to the technical materials finished with these blends

This application provides a method for preparing methylcarboxylic acid-2-propynyl ester, comprising the following steps: (1) mixing dimethyl carbonate and propargyl alcohol, adding a first alkaline catalyst, stirring and heating to a temperature of 90-105°C, and distilling out methanol by reactive distillation to obtain a first component; (2) performing solid-liquid separation on the first component to obtain a first liquid, and performing vacuum distillation on the first liquid to remove propargyl alcohol and dimethyl carbonate to obtain methylcarboxylic acid-2-propynyl ester and residue; (3) performing vacuum distillation on the residue, replenishing dimethyl carbonate and the second alkaline catalyst with the distillate for reaction, and reusing the reaction liquid in step (2). This application uses the transesterification reaction of propargyl alcohol and dimethyl carbonate to synthesize methylcarboxylic acid-2-propynyl ester, which has high safety, low overall reaction temperature, fewer by-products and waste, and high yield.

Ectoplasmic parasite infections in fish farming can cause significant difficulties and problems for the aquaculture industry. This disclosure generally relates to the treatment or control of ectopic parasite infections (such as sea lice) in fish (such as salmonids) using specific dosage regimens of isoxazoline. Specifically, the dosage regimen comprises the active ingredient shown in structural formula (I): (S)-3-methyl-N-(2-oxo-2-(prop-2-yn-1-ylamino)ethyl)-5-(5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)thiophene-2-carboxamide, including its salt, or N-oxide or solvate, at a dose of about 0.025 mg / kg / day to about 0.250 mg / kg / day, preferably about 0.025 mg / kg / day to about 0.125 mg / kg / day. Specifically, the dosage administration regimen includes oral administration for approximately 3 to approximately 10 consecutive days, preferably over a period of 7 consecutive days.

The application belongs to the technical field of pharmaceutical chemistry and pharmacology, and particularly relates to a flavanone schmidt rearrangement derivative, a preparation method and application thereof. A structural formula of the flavanone schmidt rearrangement derivative is shown in the following formula: wherein R represents one of benzyl, propynyl, allyl, isopentenyl, methyl, ethyl, isopropyl and n-butyl. The flavanone schmidt rearrangement derivative is a rearrangement compound obtained by schmidt rearrangement reaction of flavanone, and a derivative obtained by further alkylation. Pharmacological research shows that the compound has strong liver cancer cell proliferation inhibition activity, and can be applied to preparation of a drug for preventing and treating liver cancer.

This invention belongs to the field of pharmaceutical technology and discloses a novel use of S-propynylcysteine ​​or a pharmaceutically acceptable salt thereof in the preparation of a drug for the prevention and treatment of schizophrenia. The technical problem to be solved by this invention is to provide a drug for the prevention and treatment of schizophrenia based on a novel mechanism of action. The key technical points are: the drug achieves its preventive and therapeutic purpose through at least one mechanism, such as promoting the expression and / or activity of endogenous hydrogen sulfide-related enzymes, inhibiting the transcriptional activity of inflammation-related signaling pathways, and / or inhibiting pyroptosis; these mechanisms may act simultaneously or separately. The drug may further comprise a pharmaceutically acceptable carrier, excipient, or diluent. The main use of this invention is the prevention and treatment of schizophrenia.